ContraFect
28 Wells Avenue, Third Floor
Yonkers, NY 10701
United States
Tel: 914-207-2300
Website: http://www.contrafect.com/
140 articles about ContraFect
-
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
9/19/2023
ContraFect Corporation today announces that Jane Ambler, Ph.D., the Company’s Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston.
-
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
9/18/2023
ContraFect Corporation today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023.
-
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
8/28/2023
ContraFect Corporation announces that Garrett Nichols, M.D., M.S., the Company’s Interim Chief Medical Officer, will be presenting an updated overview of the Company’s DLA programs that target antibiotic-resistant pathogens at the World Anti-Microbial Congress 2023, which will be held in Philadelphia, PA from September 7-8, 2023.
-
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
8/14/2023
ContraFect Corporation announces business updates and financial results for the second quarter ended June 30, 2023.
-
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
6/27/2023
ContraFect Corporation announces that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 7.0 million shares of the company's common stock.
-
ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens
6/20/2023
ContraFect Corporation announces the presentation of data showing significant activity of its direct lytic agents against the most drug-resistant Gram-negative pathogens, including Pseudomonas aeruginosa, Klebsiella pneumoniae and Burkholderia spp, at ASM Microbe 2023 held from June 15-19, 2023 in Houston, Texas.
-
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023
6/8/2023
ContraFect Corporation announces that the Company has been selected to present four posters at the ASM Microbe Conference to be held in Houston, Texas from June 15-19, 2023.
-
ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
4/26/2023
ContraFect Corporation (Nasdaq: CFRX) today announces the first patient has been dosed in the Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infections (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS).
-
ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement
2/28/2023
ContraFect Corporation announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $10.0 million of its common stock in a registered direct offering and warrants to purchase common stock in a concurrent private placement.
-
ContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of ExebacaseTake the Deep Dive in a Virtual Fireside Chat to be Held in Q1 2023
12/19/2022
ContraFect Corporation (Nasdaq: CFRX) today announces the database lock of its Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with Staph aureus bacteremia, and a summary of the topline data and the preliminary findings from its own analysis of data from the interim futility analysis (the Futility Dataset).
-
ContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placement
12/13/2022
ContraFect Corporation announces that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $7.0 million of its common stock in a registered direct offering and warrants to purchase common stock in a concurrent private placement.
-
ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections
11/28/2022
ContraFect Corporation (Nasdaq: CFRX) announces today that ANSM, the French National Agency for the Safety of Medicines and Health Products, has authorized its Clinical Trial Application (CTA) for the study of intra-articularly administered exebacase.
-
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11/14/2022
ContraFect Corporation announced financial results and business updates for the third quarter ended September 30, 2022.
-
ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection
9/12/2022
ContraFect Corporation announces the presentation by Dr. Tristan Ferry of the Infectious and Tropical Diseases Unit, Croix-Rousse Hospital, Hôspices Civils de Lyon in Lyon, France at the 40th Annual Meeting of the European Bone and Joint Infection Society.
-
ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections
9/12/2022
ContraFect Corporation announces the publication of an editorial in the Journal of Bone and Joint Infection discussing the potential for each of the Company’s lysins, exebacase and CF-296, as additional agents in the treatment armamentarium against bone and joint infections due to their in vitro activity against coagulase-negative staphylococci, the bacteria most frequently involved in implant-associated BJIs, and their potential for both local and systemic anti-biofilm activity.
-
ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8/15/2022
ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced financial results and business updates for the second quarter ended June 30, 2022.
-
ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis
8/15/2022
ContraFect Corporation announces the publication of a manuscript in the Journal of Bone and Joint Infection, a leading peer-reviewed journal dedicated to the study of osteo-articular and soft-tissue infections.
-
ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis
7/13/2022
ContraFect Corporation (Nasdaq: CFRX), announces today that the Data Safety Monitoring Board (DSMB) of the DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped because the conditional power of the study was below the pre-specified threshold for futility.
-
Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections
6/14/2022
ContraFect Corporation (Nasdaq: CFRX) , a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today presentation data showing that the Company’s lead product candidate, exebacase was effective in a rabbit model of implant-associated osteomyelitis.
-
ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022
6/6/2022
ContraFect Corporation announces today that the Company has been selected to present two posters at the ASM Microbe Conference to be held in Washington, D.C. from June 9-13, 2022.